This week's roundup of Houston innovators includes Jason Pesterfield of Optellum, Jane Stricker of HETI, and Michael Lee of Octopus Energy. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Jason Pesterfield, CEO of Optellum

Jason Pesterfield joins the Houston Innovators Podcast to share how he plans on getting the company to commercialization right here from Houston. Photo courtesy of Optellum

Last year, Optellum, based in the United Kingdom, opened its United States headquarters in Houston, and shortly after Jason Pesterfield joined to lead the team. On a recent Houston Innovators Podcast episode, Pesterfield explained it's just the start of the company's presence in Houston.

"We're really at the beginning of it," he says. "This is the epicenter of medicine within the United States. There's no bigger or better place for health care than Houston. It's great to be a part of that and to have access to those facilities and those world class physicians and care teams." Read more.

Jane Stricker, executive director of the Houston Energy Transition Initiative at the GHP

These organizations are teaming up to advance development of a regional clean industrial hub. Photo courtesy of GHP

The Houston Energy Transition Initiative and the Center for Houston’s Future have teamed up with the Mission Possible Partnership to lead the city of Houston through the accelerated development of a regional clean industrial hub geared at decarbonization of the industrial sector, including petrochemicals, cement plants, heavy transportation, and more.

The two-year project is focused on development and deployment of clean energy projects — such as "low-carbon hydrogen, carbon capture, use and storage, electrification of industrial processes, and the production and use of low carbon fuels," according to a press release.

“There is no geography in the world better positioned to support the transition to and integration of abundant, low-carbon energy solutions than Houston," says Jane Stricker, executive director and senior vice president of HETI, in the release. "As the Energy Transition Capital of the World, Houston is leveraging its energy leadership to accelerate global solutions for a low-carbon future. This partnership with MPP is a critical component in the region’s efforts to develop and deploy technologies, policies and strategies for broad decarbonization." Read more.

Michael Lee, CEO of Octopus Energy US

Now is the time for your tech company to become a climate company, says this Houston expert. Photo via LinkedIn

In a guest column for InnovationMap, Michael Lee, CEO of Octopus Energy, called for tech innovators to change lanes to focus on the climatetech industry.

"We used to say, 'every company will become a tech company.' We’re now moving towards a world where 'every company is a climate company,'" Lee writes. "And that is creating opportunities throughout the economy for people to contribute their skills and support their families while building something that actually matters." Read more.

Jason Pesterfield, CEO of Optellum, joins the Houston Innovators Podcast to share how he plans on getting the company to commercialization right here from Houston. Photo courtesy of Optellum

Houston innovator gears up for commercialization for AI-driven lung cancer diagnostic tool

HOUSTON INNOVATORS PODCAST EPISODE 164

When a United Kingdom-based, artificial intelligence-driven lung cancer detection tool opened its United States headquarters in Houston, the company tasked Jason Pesterfield with the role of CEO to oversee international expansion and commercialization strategy. Pesterfield, who's based out of the Texas Medical Center's Innovation Institute, is familiar with the job he's been hired to do — that's because he's done it before.

After spending almost two decades at medical technology company, Stryker, Pesterfield joined St. Louis-based Veran Medical Technologies, a company also focused on lung cancer detection, and grew the business over 8 years years to a $30 million-plus annual revenue company before it was acquired by Olympus Corp. in 2020.

After assisting with the transition, he was approached by U.K.-based Optellum's Founder Timor Kadir about taking the reins of Optellum last year to again help scale the early stage digital health company.

"I'm not a computer scientist or an algorithm guy, but I do have experience in commercialization, leading teams, building culture, acquire great talent, working with my team to build a great strategy, and working with investors to make sure we're in a good financial position," Pesterfield says on the Houston Innovators Podcast.

Optellum was founded in 2016, and first entered the Houston market by way of the TMC's accelerator program and its BioBridge with the U.K. The company's technology is an AI platform that helps practitioners diagnose and treat early-stage lung cancer. The software uses natural language processing to scan medical reports of nodules in the lungs to give health care providers more information on cancer diagnostics — an analysis that takes just seconds.

"It's like having a hundred thousand sets of eyes looking over a physician's shoulder," Pesterfield says.

In September, the company raised a $14 million series A round of funding, and Pesterfield explains how that funding is being deployed to focus on growing teams within sales, B2B support, and its research and development pipeline.

He explains on the show that Optellum is just getting started with its relationship within the Houston innovation ecosystem. Pesterfield says Optellum is even on the path to securing its first Houston-based customer.

"We're really at the beginning of it," he says. "This is the epicenter of medicine within the United States. There's no bigger or better place for health care than Houston. It's great to be a part of that and to have access to those facilities and those world class physicians and care teams."

Pesterfield share more on Optellum's future on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Optellum, Liongard, and Cart.com have hired new members to their executive teams. Photos courtesy

Updated: 3 Houston startups make strategic C-suite hires

short stories

A handful of Houston tech startups have recently announced new appointments to their C-suites. A med tech company with its national headquarters in Houston has a new leader, a Houston software has a new exec focused on strategy, and a e-commerce company has a new chief revenue officer.

Optellum names new CEO

Jason Pesterfield will lead United States operations for Optellum. Photo courtesy of Optellum

Optellum, a medical software startup based in the United Kingdom and has its United States HQ in Houston, has appointed Jason Pesterfield as CEO to lead growth in the U.S. clinical market. Optellum AI-based software enhances early lung cancer diagnosis and therapy with its medical device software platform, Virtual Nodule Clinic.

Pesterfield was previously the president and CEO of Veran Medical Technologies, a leader in image-guided lung cancer diagnosis. He brings 25 years of leadership experience in the medtech sector. Optellum was founded by Václav Potěšil, Lyndsey Pickup, Timor Kadir, Professor Sir Mike Brady, and Jérôme Declerck.

"It took us almost a year to find the right successor who shares our vision and has the right expertise to take Optellum on to the next stage of growth," says Potěšil in a news release. "I am really excited to work with Jason, to make Optellum's platform available to every clinician in the USA and around the world, and to help them diagnose their lung cancer patients as early as possible. With Jason on board, I can focus on advancing Optellum's vision to transform early lung cancer therapy through partnerships that harness the power of AI software combined with molecular diagnostics, robotics and interventional devices, and drugs."

Liongard announces chief strategy officer

Patrick Schneidau is the chief strategy officer for Liongard. Photo courtesy

​Houston software-as-a-service company, Liongard, has named Patrick Schneidau as chief strategy officer. The company, founded in 2015, was a 2021 InnovationMap Awards finalist and reported that the team was looking to expand by around 70 new hires over the next year.

"Liongard is an incredible Houston growth story," Schneidau tells InnovationMap. "Our founders, Joe Alapat and Vincent Tran, have built a first-class team that allow technology service providers to operate at 10x by providing unprecedented insight and data into the systems deployed in the modern IT stack. In a rapidly growing market, they are quickly becoming 'must have' technology. I'm excited to join to team to accelerate their growth into new markets and with new products."

Schneidau spent over a decade at Houston-based PROS before serving in C-level positions at two other Houston startups — Commtrex and Truss. He's also previously served as talent committee chair for Houston Exponential.

Cart.com hires a new chief revenue officer

Randy Ray is Cart.com's first chief revenue officer. Photo courtesy of Cart.com

Fresh off its $98 million series B, Cart.com has named its first chief revenue officer. Randy Ray is tasked with driving sales growth across the company. He has over 15 years of sales and operations experience and was previously senior vice president at supply-chain solution provider High Jump.

"I've worked with the world's biggest retail and SaaS brands, and I've seen the need for a unified Ecommerce-as-a-Service hub to create operational efficiencies and unlock scalable success," Ray says in a press release. "I'm a firm believer in the Cart.com mission to drive success for online brands, and I'm looking forward to tripling our sales organization and building out a world-class revenue infrastructure as we take the company global over the next 6 to 9 months."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.